Study tests Long-Term safety of new drug for severe childhood epilepsy
NCT ID NCT05301894
Summary
This study aimed to check the long-term safety and side effects of an investigational drug called NBI-827104 in children with a rare and severe form of epilepsy. It was an extension study for children who had completed a previous trial, enrolling 19 participants. The main goal was to monitor for serious side effects over a longer period of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPTIC ENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Neurocrine Clinical Site
Orange, California, 92868, United States
-
Neurocrine Clinical Site
Aurora, Colorado, 80045, United States
-
Neurocrine Clinical Site
Washington D.C., District of Columbia, 20010, United States
-
Neurocrine Clinical Site
Miami, Florida, 33155, United States
-
Neurocrine Clinical Site
Rochester, Minnesota, 55905, United States
-
Neurocrine Clinical Site
Durham, North Carolina, 27705, United States
-
Neurocrine Clinical Site
Cleveland, Ohio, 44195, United States
-
Neurocrine Clinical Site
Dianalund, 4293, Denmark
-
Neurocrine Clinical Site
Barcelona, 08950, Spain
-
Neurocrine Clinical Site
Madrid, 28034, Spain
-
Neurocrine Clinical Site
Zurich, 8032, Switzerland
-
Neurocrine Clinical Site
London, WC1N 3JH, United Kingdom
Conditions
Explore the condition pages connected to this study.